Pilot study: performance of the Progensa PCA3 test in post-oxytocin urine specimens

Phase 4

Completed

• Conditions: prostate cancer; prostate carcinoma; 10036958

• Registration Number: NL-OMON36233
• Lead Sponsor: niversitair Medisch Centrum Sint Radboud

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 10

Inclusion Criteria

healthy male subject
>= 18 years old

Exclusion Criteria

history of prostate cancer
use of medication known to affect PSA level (eg. finasteride, dutasteride)
Symptoms of urinary tract infection

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The main study parameter is to determine yield of prostate cells (PSA mRNA) in<br /><br>the urine specimen collected after the oxytocin administration, compared to the<br /><br>yield in the urine specimen collected before oxytocin administration. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Not applicable</p><br>